- Home
- BTAI vs PMAX Comparison
BTAI vs PMAX Comparison
Compare BTAI & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- PMAX
- Stock Information
- Founded
- BTAI 2017
- PMAX 2019
- Country
- BTAI United States
- PMAX Hong Kong
- Employees
- BTAI N/A
- PMAX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- PMAX
- Sector
- BTAI Health Care
- PMAX
- Exchange
- BTAI Nasdaq
- PMAX Nasdaq
- Market Cap
- BTAI 6.6M
- PMAX 6.6M
- IPO Year
- BTAI 2018
- PMAX 2024
- Fundamental
- Price
- BTAI $2.13
- PMAX $0.44
- Analyst Decision
- BTAI Buy
- PMAX
- Analyst Count
- BTAI 4
- PMAX 0
- Target Price
- BTAI $37.00
- PMAX N/A
- AVG Volume (30 Days)
- BTAI 279.4K
- PMAX 2.1M
- Earning Date
- BTAI 03-11-2025
- PMAX 02-28-2025
- Dividend Yield
- BTAI N/A
- PMAX N/A
- EPS Growth
- BTAI N/A
- PMAX N/A
- EPS
- BTAI N/A
- PMAX 0.04
- Revenue
- BTAI $2,276,000.00
- PMAX $5,970,263.00
- Revenue This Year
- BTAI $105.36
- PMAX N/A
- Revenue Next Year
- BTAI $46.93
- PMAX N/A
- P/E Ratio
- BTAI N/A
- PMAX $10.31
- Revenue Growth
- BTAI 83.25
- PMAX 30.05
- 52 Week Low
- BTAI $2.10
- PMAX $0.34
- 52 Week High
- BTAI $56.00
- PMAX $4.70
- Technical
- Relative Strength Index (RSI)
- BTAI 28.68
- PMAX N/A
- Support Level
- BTAI $2.18
- PMAX N/A
- Resistance Level
- BTAI $2.60
- PMAX N/A
- Average True Range (ATR)
- BTAI 0.44
- PMAX 0.00
- MACD
- BTAI -0.08
- PMAX 0.00
- Stochastic Oscillator
- BTAI 0.94
- PMAX 0.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.